Dr Jesse M Neal, DDS in Alma, NE - Medicare Dentist Provider

Dr Jesse M Neal, DDS is a medicare enrolled "Dentist - General Practice" provider in Alma, Nebraska. His current practice location is 612 South St, Alma, Nebraska. You can reach out to his office (for appointments etc.) via phone at (308) 928-9010.

Dr Jesse M Neal is licensed to practice in Nebraska (license number 6425) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1043392343.

Contact Information

	Dr Jesse M Neal, DDS
	612 South St, Alma, NE 68920-2175
	(308) 928-9010
	Not Available

Healthcare Provider's Profile

Full Name	Dr Jesse M Neal
Gender	Male
Speciality	Dentist - General Practice
Location	612 South St, Alma, Nebraska
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1043392343
Provider Enumeration Date: 10/19/2006
Last Update Date: 07/08/2007

Medicare PECOS Information:

PECOS PAC ID: 9638464613
Enrollment ID: I20160830001888

Medical Identifiers

Medical identifiers for Dr Jesse M Neal such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1043392343	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1223G0001X	Dentist - General Practice	6425 (Nebraska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Jesse M Neal is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Jesse M Neal, DDS 612 South St, P O Box 807, Alma, NE 68920-2175 Ph: (308) 928-9010	Dr Jesse M Neal, DDS 612 South St, Alma, NE 68920-2175 Ph: (308) 928-9010

News Archive

Oncolytic virotherapy lends benefits to melanoma patients

Recent study published online by Melanoma Research journal indicates that melanoma patients would significantly benefit from prolonging the survival with oncolytic viroherapy treatment. The study revealed that the early stage melanoma patients treated with oncolytic medicine Rigvir were 4 to 6 times more likely to survive than those who following the current guidelines for the treatment of melanoma were only observed.

Bone marrow restores fertility in female mice

A new study from Massachusetts General Hospital (MGH) researchers confirms that female mice that receive bone marrow transplantation after fertility-destroying chemotherapy can go on to have successful pregnancies throughout their normal reproductive life.

Consumer focus on health and well-being drive demand for L-carnitine market

Consumer focus on health and well-being have driven demand for the L-carnitine market, an amino acid understood to provide distinct health benefits, according to a new report on companiesandmarkets.com. By 2017, it is expected that the L-carnitine market will achieve a value of $127.7 million.

Stimatix GI's AOS-C1000 colostomy management device meets primary, secondary endpoints in pre-clinical studies

Stimatix GI reported that the AOS-C1000(TM), a unique colostomy management device, met primary and secondary endpoints in pre-clinical in-vivo animal studies. The study was conducted under the direction of Dr. Ron Greenberg, Senior Surgeon, Department of Surgery, Sourasky Medical Center, Tel Aviv Israel. Primary endpoints of repeatable stoma sealing for continence control as well as secondary endpoints regarding tissue pathology and survival were met confirming the AOS-C1000(TM) as capable of enabling repeatable colostomy site (stoma) sealing for continence control.

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

TARIS Biomedical, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS' innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC.

Dr Jesse M Neal, DDS - Medicare Dentist in Alma, NE